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Tumor-related inflammation does influence the biological behavior of neoplastic cells 
and ultimately the patient’s outcome. With specific regard to thyroid cancer, the issue 
of tumor-associated inflammation has been extensively studied and recently reviewed. 
However, the role of chemokines, which play a crucial role in determining the immuno- 
phenotype of tumor-related inflammation, was not addressed in previous reviews on 
the topic. Experimental evidence shows that thyroid cancer cells actively secrete a wide 
spectrum of chemokines and, at least for some of them, solid scientific data support 
a role for these immune-active molecules in the aggressive behavior of the tumor. Our 
proposal for a review article on chemokines and thyroid cancer stems from the notion 
that chemokines, besides having the ability to attract and maintain immune cells at the 
tumor site, also produce several pro-tumorigenic actions, which include proangioge-
netic, cytoproliferative, and pro-metastatic effects. Studies taking into account the role 
of CCL15, C–X–C motif ligand 12, CXCL16, CXCL1, CCL20, and CCL2 in the context 
of thyroid cancer will be reviewed with particular emphasis on CXCL8. The reason for 
focusing on CXCL8 is that this chemokine is the most studied one in human malignancies, 
displaying multifaceted pro-tumorigenic effects. These include enhancement of tumor 
cells growth, metastatization, and angiogenesis overall contributing to the progression 
of several cancers including thyroid cancer. We aim at reviewing current knowledge 
on the (i) ability of both normal and tumor thyroid cells to secrete CXCL8; (ii) direct/
indirect pro-tumorigenic effects of CXCL8 demonstrated by in vitro and in vivo studies 
specifically performed on thyroid cancer cells; and (iii) pharmacologic strategies proven 
to be effective for lowering CXCL8 secretion and/or its effects on thyroid cancer cells.
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TUMOR-ReLATeD iNFLAMMATiON
Inflammation is a physiologic protective process used by the organism in response to tissue damage. 
The strong relationship between inflammation and the development, maintenance and progression 
of cancer was hypothesized for the first time in the far 1863 (1) by Virchow. His observation that 
leukocytes infiltrate neoplastic tissues provided evidence for a connection between inflammation 
and cancer (2). Subsequently, inflammation was more specifically related to tumorigenesis because 
of its ability to favor genome instability, tumor cell growth, and angiogenesis. Accumulation of 
immune cells was also shown to influence tissue homeostasis. Thus, inflammation is currently 
regarded as an essential component of malignancies (3).
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Further advances led to the identification of “inflammatory 
hallmarks” of cancer, which include inflammatory cells, inflam-
matory mediators, and factors involved in tissue remodeling–
repair and angiogenesis. It is important to note that inflammatory 
features were also found in those tumors for which a firm causal 
relationship with inflammation was not established (4). As a 
consequence, the original notion that “inflammation causes 
cancer” was progressively changed to “not only inflammation 
can cause cancer, but also cancer can cause inflammation” (5). 
The above statement mainly relies upon the demonstration that 
oncogenic changes specifically promote the de novo production 
of inflammatory mediators (5). Further evidence supporting 
this novel view of the events derives from the observation that 
cancer cells can “manipulate” their microenvironment to escape 
immune surveillance. While inflammatory cells may recognize 
tumor cells as antigens, the tumor microenvironment itself is a 
source of factors that suppress antitumor immune responses (6).
Chemokines represent a crucial component of the network 
of inflammatory mediators associated with cancer and are by no 
doubts the most extensively characterized molecules involved 
in the maintenance and progression of tumor-related inflam-
mation (7).
CHeMOKiNeS AND TUMOR 
MiCROeNviRONMeNT
Several studies in cancer patients showed that the inflamma-
tory profile of tumor microenvironment is closely related to its 
biological behavior (8–10). Moreover, growing evidence recently 
reviewed, suggested that the composition of tumor microenvi-
ronment affects the therapeutic outcome of the patient (11, 12). 
The tumor microenvironment is made of extracellular matrix and 
stromal cells, which include fibroblasts, vessel cells (endothelial 
cells, pericytes, and smooth muscle cells), and inflammatory 
leukocytes [lymphocytes, macrophages, dendritic cells (DCs), 
mast cells, and neutrophils] (13). These cells, either alone or in 
combination, potentially contribute to tumor growth, being their 
recruitment regulated by the presence of specific chemokines 
(13). Tumor cells secrete several chemokines and chemokine 
receptors were identified on their surface at different levels of 
expression (14). According to current knowledge, the expres-
sion of specific chemokines and their receptors in tumor cells 
play a dual role in the oncogenic process (15). On the one hand, 
secreted chemokines by cancer-initiating cells and by normal 
surrounding cells may limit neoplastic progression by increas-
ing leukocyte migration within the tumor, which eventually 
results in the induction of long-term antitumor immunity (15). 
Opposite to this process, other chemokines may facilitate tumor 
cell growth: (i) by recruiting endothelial cells; (ii) by subverting 
immunologic surveillance; and (iii) by maneuvering the tumor 
leukocyte profile, thus making feasible the escape from antitumor 
immune surveillance. More importantly, chemokines produced 
by tumor cells are believed to be involved in the metastatic pro-
cess (15–17). Thus, tumor cells actively secrete and, owing to the 
presence of specific receptors on their cell membrane, respond 
to chemokines, which represent essential mediators influencing 
tumor progression (Figure 1).
THYROiD CANCeR
Thyroid cancer, the most prevalent endocrine malignancy, 
showed a sharp increase in its incidence in the last years, prob-
ably due to the routine use of neck ultrasound (18). Among all 
malignancies, the prevalence of thyroid cancer is relatively low 
(less than 1% of all malignant tumors in humans), but benign 
nodules are extremely frequent in the general population. Thus, 
the differential diagnosis between benign and malignant nodules 
is of great clinical relevance, to reduce the number of unnecessary 
thyroidectomies. Although the majority of differentiated thyroid 
cancers are slow growing and clinically indolent malignancies 
associated with an overall good prognosis (18), a recent survey 
reported a trend for increased mortality rate, mainly due to 
advanced-stage papillary thyroid cancer (PTC) (17). The avail-
ability of markers of thyroid cancer aggressiveness would allow 
the use of targeted therapies in selected cases, thus reducing the 
risk of over treating the vast majority of patients (18–20).
Thyroid Cancer Microenvironment
Similar to other human malignancies, thyroid cancer microen-
vironment is composed of a mixture of immune cells (macro-
phages, mast cells, neutrophils, and lymphocytes) and soluble 
mediators (chemokines, cytokines, and growth factors), which 
are present within and nearby the primary thyroid tumor 
(21–23). Chemokines, which attract specific subpopulations of 
immune cell into the tumor site, are active immune mediators 
playing a role in thyroid tumor progression. Several in vitro and 
in vivo studies evaluated the role of chemokines in thyroid cancer 
and provided evidence for their ability to attract and maintain 
immune cells at the tumor site. Moreover, specific chemokines 
exert on thyroid cancer cells pro-tumorigenic actions, which 
include proangiogenetic, cytoproliferative, and pro-metastatic 
effects (24).
Chemokines and Thyroid Cancer
Chemokines are a family of structurally related pro-inflammatory 
peptides of low-molecular weight, characterized by chemotactic 
activity. Originally, it was believed that the only function of 
chemokines was to recruit leukocytes to inflammatory sites. 
Subsequently, it was shown that chemokines also play a role in 
tumor cell growth, angiogenesis, and organ sclerosis. Currently, 
chemokines are classified in four families named C, CXC, CX3C, 
and CC according to the presence of a conserved amino-proximal 
cysteine residue in their NH2 terminal portion (23, 25, 26). 
With specific regard to thyroid cancer, a number of chemokines 
have been investigated for their antitumor or tumor-promoting 
activity.
Chemokines with Antitumor effects  
in Thyroid Cancer
CXC Motif Ligand 10
CXC motif ligand 10, previously known as interferon (IFN)-
γ-induced protein 10 (IP-10), is secreted by several cell types 
(T lymphocytes, neutrophils, monocytes, endothelial cells, fibro-
blasts, keratinocytes, and pre-adipocytes), and also by normal 
thyroid cells (25, 27, 28). It binds the chemokine receptor CXCR3. 
FigURe 1 | Effects of chemokines in the Tumor microenvironment. The presence of endothelial cells, pericytes and smooth muscle cells lymphocytes, 
macrophages, dendritic cells, mast cells, and neutrophils attracted by specific chemokines influences tumor growth. Chemokines secreted in tumor 
microenvironment play a dual role in the oncogenic process. Some chemokines (green) may facilitate tumor cell growth by: (i) recruiting endothelial cells;  
(ii) subverting immunologic surveillance; (iii) maneuvering the tumor leukocyte profile to escape antitumor immune surveillance, and (iv) inducing metastatic  
process. Other chemokines may limit neoplastic development (red) by: (i) increasing leukocyte migration and (ii) inducing long-term antitumor immunity.
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CXCL10 is generally viewed as a mediator of host immune 
response, specifically T helper 1 cells, and its role in autoimmune 
endocrine diseases is well known (25, 27, 29, 30). Data derived 
from studies in other human malignancies support an antitumor 
effect for CXCL10, due to its anti-angiogenic properties (31). 
It was shown that CXCL10, being secreted within the tumor, 
attenuates the process of new vessels formation and leads to 
reduced tumor growth in non-small cell lung cancer (31, 32). A 
higher expression of CXCL10 was also related to an improved 
survival of patients with colon–rectal cancer (31, 33). In line with 
these observations, neutralization studies using anti-CXCL10 
antibody demonstrated that this chemokine inhibits angiogenesis 
and chemotaxis in models of murine colon, mammary, and lung 
cancer (34). These antitumor effects of CXCL10 are supposed 
to be, at least in part, related to promotion of immune activities 
against tumor cells (31).
Although the antitumor effects of CXCL10 were not deeply 
investigated in thyroid cancer, currently available evidence 
indicates that: (i) oncogenic RET/PTC rearrangements and/
or activating mutations of BRAF and RAS oncogenes activate 
a transcriptional program in PTC cells, which also involves an 
upregulation of CXCL10 (35); (ii) in thyroid PCCL3 cancer 
cells, RET/PTC rearrangements result in the early activation 
of genes being involved in the regulation of CXCL10 (36); and 
(iii) when compared with normal thyroid cells, PTC cells show 
a nearly 10-fold higher secretion of CXCL10 after stimulation 
with IFN-γ + TNF-α (37). The significance of the above findings 
in thyroid cancer remains to be elucidated, but data from other 
malignancies support the hypothesis that CXCL10 might have an 
antitumor effect.
Chemokines with Tumor-Promoting 
effects in Thyroid Cancer
Several chemokines are currently blamed for a tumor-promoting 
activity in thyroid cancer (Table 1).
CCL15
CCL15, a potent chemoattractant for leukocytes and endothelial 
cells, binds the receptor CCR1 (56, 57). A recent in vitro study 
showed that CCL15 produced by follicular thyroid cancer cells 
is responsible for the recruitment of tumor-associated mac-
rophages (TAMs) (38). TAMs are infiltrating inflammatory cells, 
which may comprise as much as 50% of the tumor mass (58). 
Their presence was found to be positively correlated with thyroid 
cancer cell growth and metastatic potential, and with a reduced 
patient’s survival (38, 51). The concentrations of CCL15 were 
reported to be significantly greater in follicular cancers when 
compared with follicular adenomas. This observation might 
imply that estimating the amount of TAMs (being attracted by 
CCL15) in follicular thyroid lesions would be clinically useful 
TAbLe 1 | Chemokines with pro-tumorigenic effects in thyroid cancer microenvironment.
Family Nomenclature (older names in 
brackets)
Receptors Role in thyroid cancer Reference
CC CCL15 (MIP-1 δ, LKN-1, HCC-2, 
MIP-5, NCC-3)
CCR1, CCR3 Recruits TAMs (38)
CXC CXCL12 (SDF-1α/β) CXCR4, CXCR7 Regulates neoplastic cell migration in PTC (39, 40)
CXC CXCL16 (SR-PSOX) CXCR6 Favors migration of neoplastic cells (41)
CXC CXCL1 (GRO-α) CXCR1, CXCR2 Favors proliferation, survival, and invasive behavior of thyroid cancer cells (42)
CC CCL20 (LARC, MIP3α) CCR6 Favors recruitment of DCs and neoplastic cell migration in PTC (43–48)
CC CCL2 (MCP-1) CCR2 Recruits TAMs (49, 50)
CXC CXCL8 (IL-8, NAP-1) CXCR1, CXCR2 Favors neutrophils recruitment, migration of neoplastic cells, EMT,  
and cell proliferation
(51–55)
TAMs, tumor-associated macrophages; PTC, papillary thyroid cancer; DCs, dendritic cells; EMT, epithelial–mesenchymal transition; NAP-1, neutrophil attractant/activation protein-1; 
IL-8, interleukin-8; LARC, liver activation regulated chemokine; MIP3α, macrophage inflammatory protein-3; MCP-1, monocyte chemoattractant protein-1; CXCL12, C–X–C motif 
ligand 12.
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for the pre-surgery differentiation of follicular cancer from 
follicular adenoma (38).
CXC Motif Ligand 12
CXC motif ligand 12, also known as stromal cell-derived fac-
tor-1, binds to the CXCR4 (39) and to the CXCR7 receptors 
(59, 60). CXCL12 displays a strong chemotactic power toward 
lymphocytes, and it is known to play an important role in 
angiogenesis and tumor cell migration (39). The expression of 
CXCL12, CXCR4, and CXCR7 was detected in thyroid cancer 
tissue specimens (39, 61–63). Chung et al. demonstrated that, 
compared with non-cancerous thyroid lesions, CXCL12 is typi-
cally overexpressed in human PTC, regardless of its histologic 
subtypes. In this study, the sensitivity and specificity of using 
CXCL12 as a diagnostic marker for PTC was 90.8 and 96.8%, 
respectively (39). Immunohistochemistry studies also showed 
that 90% of PTC specimens were positive for CXCL12, whereas 
only 10.5% of follicular thyroid cancers showed positive stain-
ing for this chemokine (63). The absence of CXCL12 in non-
cancerous thyroid lesions and in other thyroid malignancies, 
such as medullary and anaplastic thyroid cancers, supported the 
opinion that CXCL12 is specifically associated with PTC (40). 
In a subsequent study, the same authors provided evidence that 
the CXCL12–CXCR4/CXCR7 axis exerts its action in thyroid 
cancer cells by increasing their migration and invasiveness via 
Akt (also known as protein kinase B) and extracellular signal-
regulated kinase signaling, and by activating matrix metallopro-
teinase-2 (40).
CXCL16
CXCL16 is a ligand for CXCR6 and signals through the Akt 
pathway (64). CXCL16 is abundantly present in the conditioned 
medium of macrophage–PTC cells co-cultures, being mainly 
produced by PTC-stimulated macrophages (41). Cho et al. dem-
onstrated that an anti-CXCL16 neutralizing antibody, as well as 
an Akt inhibitor, attenuated the macrophage-dependent migra-
tion of PTC cells. This finding suggests that CXCL16 is involved 
in the macrophage-mediated actions promoting migration and 
invasiveness of PTC cells. In line with these data, the expression of 
CXCL16 and of another chemokine (CXCR6) was associated with 
the presence of lymph node metastasis in patients with PTC (41).
CXCL1
CXCL1, previously named GRO-α, is a growth factor that binds 
the CXCR2 receptor, and it is classically viewed as a chemoat-
tractant for neutrophils. CXCL1 was found to be highly expressed 
in normal and pathologic thyroid tissue (65). An indirect role 
for CXCL1 in thyroid cancer progression was hypothesized in a 
study performed on mast cells (42). Mast cells are present in the 
tumor microenvironment where they influence angiogenesis and 
tumor invasion of the extracellular matrix by releasing cytokines 
and proteases (66–69). Mast cell-released mediators enhance 
proliferation, survival, and invasive behavior of thyroid cancer 
cells in  vitro. Furthermore, mast cells promote the growth of 
thyroid carcinoma xenografts in nude mice (42). It is known that 
a complex mixture of mediators, contained in thyroid cancer 
cells conditioned medium, is responsible for mast cell activation. 
Although these mediators remain to be fully identified, Melillo 
et al. hypothesized that CXCL1 could mediate the proliferative 
effect of mast cell conditioned medium on thyroid carcinoma 
cell lines (42). Indeed, the addition of CXCL1 to the immune-
depleted mast cell-conditioned medium rescued the proliferating 
effect of the complete medium.
CCL20
As a member of the CC-chemokine family, chemokine ligand 20 
(CCL20), also named liver activation-regulated chemokine or 
macrophage inflammatory protein-3, is the exclusive ligand for 
the CCR6 receptor (70). The gene encoding for CCL20 belongs 
to the group of chemokine genes, which are highly expressed 
in PTC specimens compared with normal thyroid tissue (43). 
Its receptor (CCR6) was also found to be highly expressed in 
thyroid cancer cells (44). Immunohistochemical analysis demon-
strated that CCL20 is strongly and diffusely expressed in tumor 
cells of the majority of well and poorly differentiated PTC. Only 
a minority of follicular carcinomas stained positive for CCL20, 
which was not detected in follicular adenoma or normal thyroid 
tissue (45). A subsequent flow cytometry study confirmed that 
CCR6 is expressed on a relevant proportion of TPC-1 (bearing 
the RET/PTC rearrangement) and BCPAP (bearing the BRAF 
mutation) tumor cells, but not in normal human thyroid cells 
in basal conditions. TNF-α induced a significant increase in the 
percentage of cells expressing CCR6, both in TPC-1 and BCPAP 
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tumor cell lines, but not in normal human thyroid cells (46). 
TNF-α treatment increased the CCL20-promoted migration 
of TPC-1 and BCPAP tumor cells, but a similar effect was not 
observed in normal human thyroid cells (46). These actions of 
CCL20 resulted in the acquisition of a more aggressive behavior 
by the tumor. In agreement with these findings, previous obser-
vations indicated that the overexpression of CCR6 enhances the 
aggressiveness of colon–rectal cancer (71). The specificity of this 
CCL20–CCR6 interaction was demonstrated by the fact that 
CCR6 knockdown inhibits the CCL20-induced invasiveness and 
migration of thyroid cancer cells (47).
The role of CCL20–CCR6 interplay was further characterized 
by Scarpino et al. who provided evidence that this interaction is 
required for the migration of immature DCs in PTC (72). Indeed, 
CCR6 is exclusively expressed in human immature DC, which 
predominate in the immune infiltrate of PTC (45, 72, 73). These 
data indicate that in PTC the secretion of CCL20 by tumor cells 
promotes the migration of CCR6+ immature DC into the tumor. 
This notion is of particular relevance because the burden of DC 
infiltration was demonstrated to be closely linked to the prognosis 
of several malignant tumors (74–77) including, at least in some 
investigators’ view, thyroid cancer (78, 79).
CCL2
The identification of CCL2 (chemokine monocyte chemoattract-
ant protein-1) and its receptor CCR2 (80) greatly contributed to 
the studies evaluating the mechanisms of monocyte trafficking 
during inflammatory responses and cancer development. The 
secretion of CCL2 has been demonstrated in several cancer 
cell types (7), but data in thyroid cancer are scanty. Tanaka 
et al. found a significant relationship between the expression of 
CCL2 in tumor cells and the presence of lymph node metastases 
in patients with PTC. Furthermore, higher expression levels 
of CCL2 characterized those patients with recurrent PTC as 
opposed to the successfully cured ones (49). The role of CCL2 
in promoting TAM infiltration in PTC emerged after the find-
ing that the oncogenic activation of BRAF in murine thyroids 
increased the expression of CCL2, which was rapidly followed 
by a robust recruitment of TAM expressing the CCR2 receptor. 
Furthermore, the selective targeting of CCR2-expressing cells 
during BRAF activation significantly reduced TAM density and 
retarded the development and progression of PTC. Targeting 
CCR2-positive cells in mice bearing an advanced PTC resulted 
in a reduced TAM density and in the regression of smaller, more 
differentiated, thyroid cancer foci containing fewer tall cells and 
poorly differentiated areas (50).
CXCL8
At present, CXCL8 is probably the most studied chemokine in 
human cancer (81). Before addressing the link between CXCL8 
and thyroid cancer, we will briefly review current evidence dem-
onstrating the crucial role of CXCL8 in human malignancies of 
non-thyroid origin.
CXCL8 and Malignancies of Non-Thyroid Origin
CXCL8 is still often referred to as interleukin-8 or neutrophil 
attractant/activation protein-1 (52, 82). CXCL8 was first 
identified for its role in attracting neutrophils and other inflam-
matory cells, both to inflammation and tissue injury sites. The 
discovery of CXCL8 represented a landmark in immunology, 
because this chemokine was the first immune molecule found 
to have a chemoattractant activity on selected subpopulations of 
leukocytes (82, 83).
Neutrophils expressing CXCR1 and CXCR2 are attracted to 
the tumor site following a gradient of concentration of CXCL8 
secreted by tumor cells. The presence of neutrophils in the tumor 
microenvironment is of great relevance. Indeed, once in site, neu-
trophils release enzymes, which are responsible for remodeling 
the extracellular matrix. This effect facilitate the migration of 
tumor cells and their entry in the vascular bed, thus allowing the 
travel to metastatic sites (84). However, the spectrum of CXCL8 
actions is much wider. Besides acting as a chemoattractant, the 
binding of CXCL8 to its receptors (CXCR1 and CXCR2) results 
in the activation of CXCR1/CXCR2-expressing cells (85, 86). 
The expression of the CXCL8 gene and the subsequent secre-
tion of the correspondent protein are primarily regulated by the 
transcription factors nuclear factor-κB (NF-κB) and activator 
protein-1 (AP1). However, experimental evidence suggests that 
other, yet to be unveiled, pathways are also involved (87). Owing 
to its potent pro-inflammatory properties, CXCL8 expression in 
normal tissues is low or undetectable (81), while an increased 
expression of CXCL8 was detected in several human solid 
tumors such as melanoma (88), squamous cell carcinoma (89), 
cervical (90), ovarian (91), non-small cell lung (92), colon (93), 
and gastric (94) cancers. Brain, breast, kidney, prostate, and 
thyroid cancers, as well as hematological malignancies (acute 
myelogenous leukemia, chronic lymphocytic leukemia, and 
Hodgkin’s lymphoma), also showed an increased expression of 
CXCL8 (81). The widespread expression of CXCL8 in human 
malignancies is of particular relevance, because the recently 
identified pleiotropic effects of this chemokine influence cell 
growth, angiogenesis, invasiveness, and metastatic potential.
Following its secretion by cancer cells, CXCL8 can enhance 
their proliferation rate and survival through autocrine signal-
ing pathways. CXCL8 signaling triggers the epidermal growth 
factor receptor, thus promoting the downstream activation of 
the mitogen-activated protein kinase (MAPK) signaling via the 
monomeric small G protein, Ras-GTPase (95, 96). In several 
cancer cell lines, it was demonstrated that the activation of MAPK 
by CXCL8 results in increased cell proliferation and survival 
(93, 95–99). As shown in melanoma and in cancers of the liver, 
pancreas, and colon–rectum (100–103), CXCL8 functions as an 
autocrine growth factor.
The growth of solid tumors is dependent on the development 
of new blood vessels from preexisting capillaries, thus fulfilling 
the need of feeding cancer cells. Angiogenesis is a critical process 
in the development of malignancy and occurs in various stages 
of tumor progression. The formation of new blood vessels and 
lymphatics is a complex process characterized by multistep 
events, which require the intervention of proangiogenic factors, 
among which CXCL8 is a powerful one (104). The proangiogenic 
effect of CXCL8 was first demonstrated by Strieter et al. in the 
rabbit cornea (105) and further characterized in different types of 
cancer. The angiogenic effect of CXCL8 occurs after its binding to 
TAbLe 2 | Multifaceted tumor-promoting actions of CXCL8.
CXCL8 effects evaluation Type of cancer cells Reference
Tumor cell growth In vitro Liver, pancreas, colon, colon–rectum, gastric, ovarian,  
non-small lung, prostate
(93, 95–102)
Angiogenesis In vitro in vivo Breast, gastric, gastrointestinal (101,104–108)
Induction of EMT and/or stemness In vitro in vivo Colon, nasopharyngeal, breast, colon, non-small lung, thyroid (87, 109–119)
Formation of spheres, self-renewal of stem cells, 
and tumor-initiating ability
In vitro Thyroid cancer stem cells (55)
Induction of neoplastic cell migration In vitro Thyroid cells TPC-1 and BCPAP (121)
Increase of metastatic spread In vivo Bladder, thyroid (51, 87, 109, 110)
TPC-1, papillary thyroid cancer cell line with RET/PTC rearrangement; BCPAP, papillary thyroid cancer cell line with BRAFV600e mutation; EMT, epithelial–mesenchymal transition.
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CXCR1 and CXCR2 receptors, which are expressed by endothe-
lial cells (104). This binding results in endothelial cells activation, 
chemotaxis (as shown by in vitro experiments), and formation of 
new blood vessels in vivo (106, 107). This process is exemplified 
by the observation that in human gastrointestinal cancer (94) the 
concentrations of CXCL8 in tissues and in the circulation are cor-
related with the amount of new blood vessels within the tumor.
In xenografted and orthotopic in  vivo models of cancer 
(86, 108–110), the metastatic potential of many solid tumors was 
found to be positively related with the secretion of CXCL8. The 
action of CXCL8 is mainly exerted through the recruitment of 
neutrophils (moving from blood vessels to the tumor site), which 
enable the migration of tumor cells. Thus, it is currently accepted 
that CXCL8 has pro-metastatic properties. Further support to this 
statement stems from the demonstration that CXCL8 is strongly 
involved in the epithelial–mesenchymal transition (EMT), 
a complex molecular program, whereby epithelial cells lose 
their typical features (i.e., apical–basolateral polarity, extensive 
intercellular adhesions, and contact growth inhibition) in favor 
of acquiring mesenchymal features, which include edge trailing, 
edge asymmetry, and loss of intercellular contact. Motility and 
invasiveness are also increased (111, 112). These CXCL8-induced 
changes were characterized in cells deriving from cancers of the 
colon (113), of the nasopharynx (114), and of the breast (115). 
The tumor-promoting effect of CXCL8 is further strengthened 
by the observation that, while this chemokine promotes EMT, 
EMT by itself promotes CXCL8 secretion, thus producing a 
loop-reinforcing cascade, which was demonstrated in colon and 
breast cancer cells (116, 117). Several mechanisms are likely to 
be involved in this process: (i) the aberrant nuclear localization 
of the tight junction protein ZO-1, which, being associated with 
EMT, leads to enhanced CXCL8 expression (118); (ii) the over-
expression of Snail, a zinc-finger transcriptional repressor tightly 
controlling EMT (119), which directly activates the transcription 
of CXCL8 by binding E-boxes within the CXCL8 gene promoter 
(113, 120). A summary of the multifaceted pro tumorigenic 
effects of CXCL8 in cancer is given in Table 2.
Based on the multifaceted tumor-promoting effects of CXCL8, 
the possibility to use this chemokine as a tumor biomarker 
appeared a fascinating perspective. With this aim, several studies 
measured the concentrations of CXCL8 in the serum and in tis-
sues of cancer patients. The results of these studies indicated that 
the concentrations of CXCL8 are higher in cancer patients com-
pared with healthy controls. In several types of cancer including 
melanoma, renal cell carcinoma, non-small cell lung cancer, and 
hepatocellular carcinoma, the levels of CXCL8, as measured in 
serum and in tissues, correlate with tumor size, depth of infiltra-
tion, stage, and prognosis (122). Moreover, Broutin et al. found 
significantly higher circulating levels of CXCL8 in metastatic 
medullary thyroid cancer patients as opposed to healthy donors 
(123). As far as DTC is concerned limited studies are available. 
However, two independent studies reported higher circulating 
concentrations of CXCL8 in patients with DTC as opposed to 
patients with benign nodules (124, 125). From a clinical point of 
view, the main message stemming from these results is that lower 
serum levels of CXCL8 characterize a less aggressive course of 
malignancy and a better response to anticancer therapy (122).
CXCL8 and Thyroid Cancer
At present, CXCL8, in view of its proven pro-tumorigenic effects, 
is the most extensively investigated chemokine involved in thy-
roid cancer. In this section, we will review currently available data 
regarding: (i) the ability of both normal and tumor thyroid cells to 
secrete CXCL8; (ii) the direct/indirect pro-tumorigenic effects of 
CXCL8, as shown by in vitro and in vivo studies in thyroid cancer 
cells; and (iii) the pharmacologic strategies for lowering CXCL8 
secretion and/or for targeting its effects in thyroid cancer.
Secretion of CXCL8 by Thyroid Cells
The link between CXCL8 and the thyroid was discovered in the 
far 1992, when the first demonstration was provided that normal 
thyroid cells in primary culture secrete CXCL8 (126). More 
recent studies demonstrated that iodide positively regulates the 
expression of the CXCL8 gene (127) and that TSH induces the 
production of CXCL8 in Graves’ disease derived peripheral blood 
fibrocytes expressing the TSH receptor. These findings suggested 
that CXCL8 is somehow linked to thyroid homeostasis (128).
Initially, CXCL8 was hypothesized to play a role in the devel-
opment of autoimmune thyroid diseases (129). More recently, the 
involvement of CXCL8 in thyroid oncogenesis emerged as a new 
frontier of research (129). The first demonstration that thyroid 
cancer cells secrete CXCL8 was provided by Yoshida et al., who 
reported that this chemokine was secreted by KHM-5M cells 
obtained from an undifferentiated thyroid cancer (53). The 
presence of a neutrophil infiltrate within the tumor of nude mice 
transplanted with KHM-5M cancer cells strongly supported a role 
for CXCL8 produced by neoplastic thyroid cells in the recruitment 
of neutrophils at the tumor site. Subsequently, it was found that, 
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besides KHM-5M cells, neoplastic cells derived from other types 
of thyroid cancer secrete CXCL8, which is involved in thyroid 
cancer-related inflammation. In 2002, Basolo et al. showed that 
CXCL8 is the most abundant chemokine being secreted in cell 
culture supernatants of papillary, anaplastic, and poorly differen-
tiated thyroid carcinoma cell lines (130). In agreement with these 
findings, Borrello et al. demonstrated that the pro-inflammatory 
program elicited by RET-PTC rearrangement stimulates a panel 
of chemokine genes among which the CXCL8 gene is the main 
upregulated one. As a consequence, the correspondent protein 
is the main secretory product (131). Subsequently, Muzza et al. 
found a significantly higher expression of the CXCL8 gene in PTC 
specimens (43). More importantly, the CXCL8 gene was found 
to be similarly expressed in non-neoplastic tissue specimens 
of thyroiditis and in normal thyroid tissue. This observation, 
besides being an indirect confirmation that CXCL8 has a minor 
if any role in autoimmune thyroid diseases, strongly supports the 
concept that the cytokine/chemokine milieu sustaining chronic 
autoimmune thyroiditis is different from that involved in thyroid 
tumor-related inflammation (43, 54, 129).
The modality of CXCL8 secretion by thyroid cancer cells 
was investigated in several studies. Currently, available evidence 
indicates that TPC-1 (RET/PTC1 mutated) and BCPAP (BRAF-
V600E mutated) thyroid tumor cells secrete significantly different 
amounts of CXCL8 as measured in the cell culture supernatants, 
both basally and after TNF-α stimulation (132). BCPAP cells 
displayed a higher basal secretion of CXCL8, but their response 
to TNF-α was smaller than that of TPC-1 cells (132). The main 
concept emerging from these in  vitro data is that the type of 
oncogenic lesion harbored by thyroid cancer cells accounts 
for their different ability to secrete CXCL8. In line with this 
interpretation, Zhang et al. showed that, among PTC cells, those 
overexpressing the chemokine receptor CXCR7 (the receptor for 
CXCL12) secrete higher amounts of CXCL8, which reverts fol-
lowing CXCR7 inhibition (133). Going deeper in understanding 
the mechanisms responsible for CXCL8 secretion is a compli-
cated issue, because CXCL8 secretion can be induced both by 
exogenous and by endogenous (at the DNA level) factors. 
Accordingly, a number of different stimuli, including inflamma-
tory signals (e.g., TNF-α and IL-1β), chemical and environ mental 
factors (e.g., chemotherapy agents and hypoxia), and steroid 
hormones (e.g., androgens, estrogens, and dexamethasone), all 
contribute in regulating the expression of CXCL8 (86, 134).
Pro-Tumorigenic Effects of CXCL8 in Thyroid Cancer
While solid evidence already indicated that thyroid cancer cells 
secrete CXCL8, the role of this chemokine in influencing the 
biological behavior of thyroid cancer and more specifically its 
pro-tumorigenic effect had to be established. At present, a widely 
addressed topic regards the ability of CXCL8 to promote the meta-
static spread of thyroid cancer cells. In line with what reported in 
other human malignancies, Visciano et al. elegantly demonstrated 
that CXCL8 is the main mediator of stemness and of EMT in 
thyroid cancer cells (55). Incubation of mast cells with thyroid 
cancer cell-derived conditioned medium produced a strong 
upregulation of a set of selected cytokines (TNF-α, CXCL6, and 
CXCL8), which consistently induced EMT in thyroid cancer cells. 
Immune depletion experiments not only identified CXCL8 as the 
most powerful inducer of EMT but also provided evidence that the 
presence of CXCL8 is a necessary condition for inducing EMT in 
thyroid cancer cells. The authors also demonstrated that this effect 
would be exerted through an Akt–Slug-dependent pathway (55). 
In particular, the in vitro inhibition of Akt (a downstream media-
tor of CXCL8 action), prevented Slug accumulation (an important 
mediator of EMT and Stemness), eventually blocking EMT and 
stemness of thyroid cancer cells. Thus, CXCL8 signaling appears 
to be a crucial step in this oncogenic pathway (55). The same group 
of investigators showed that CXCL8, through an autocrine circuit 
mediated by the CXCR1 receptor, is involved in the formation of 
spheres, in their self-renewal and in the tumor-initiating ability 
of thyroid cancer stem cells. The identification of this autocrine 
pro-tumorigenic action of CXCL8 is of great relevance, because 
it clearly indicates that targeting the CXCL8–CXCR1 circuit 
could produce therapeutic benefits, at least in patients bearing 
an aggressive radioiodine-refractory thyroid cancer (135). In line 
with the above reported findings, it was shown that the incubation 
of TPC-1 and BCPAP thyroid cancer cell lines with recombinant 
human (rh)-CXCL8, significantly increased cell migration, as 
assessed by an in vitro migration assays (121).
Moving to in vivo experiences, the involvement of CXCL8 in 
the metastatic process of thyroid cancer cells was studied in NOD/
SCID mice transfected with a thyroid cancer cell line. Treatment 
with rh-CXCL8 significantly increased the metastatic spread, 
ultimately resulting in an increased mortality. These data unam-
biguously proved that the administration of exogenous CXCL8 
has a powerful pro-metastatic role, at least in this animal model of 
thyroid cancer (51). It was hypothesized that CXCL8 would exert 
its active role in thyroid cancer progression by paracrine binding 
to CXCR1 and CXCR2 expressed on the surface of PTC cells (51). 
A comprehensive scheme of the multifaceted pro-tumorigenic 
effects of CXCL8 in thyroid cancer is given in Figure 2.
In line with in  vitro findings and data from animal studies, 
Bauerle et al. reported that patients with high-risk thyroid cancer 
display significantly higher intra-tumor levels of CXCL8 mRNA 
than those found in patients with low-risk disease (136). These 
data give indirect support to the existence of a positive relation 
between higher intra-tumor CXCL8 levels and a more aggressive 
course of thyroid cancer. The only study in which the circulating 
levels of CXCL8 were measured in patients with PTC reported 
significantly higher concentrations of CXCL8 in affected patients 
when compared with healthy controls (137). Although these results 
derive from a single study, they are in line with those performed in 
patients affected by other types of cancer. Taken together, in vitro 
and in vivo data provide evidence for an action of CXCL8 as tumor-
promoting agent and indicate that lowering CXCL8 levels in 
thyroid cancer microenvironment could be of therapeutic benefits.
Strategies for Reducing CXCL8 Effects  
in Cancers of Non-Thyroid Origin
Targeting CXCL8
Moving from the idea that lowering the levels of CXCL8 would 
result in the attenuation of its pro-tumorigenic effects, several 
attempts were done to reduce CXCL8 production by cancer cells 
or to block its effects. The neutralization of CXCL8 via ABX-IL8 
FigURe 2 | Multifaceted pro-tumorigenic effects of CXCL8 in thyroid cancer microenvironment. CXCL8, being produced by both normal and tumor thyroid cells, 
exerts a chemotactic action on circulating immune cells (expressing CXCR1 and CXCR2), which further secrete CXCL8. The presence of TNFα, Ilβ, and other 
CXCL8 stimulating factors in the thyroid cancer microenvironments induces an upregulation of the CXCL8 secretion by both normal and cancer thyroid cells. The 
expression of CXCR1 and CXCR2 on thyroid tumor cells accounts for the autocrine/paracrine signaling exerted by CXCL8 secreted by normal thyroid cells, thyroid 
cancer cells themselves, and infiltrating immune cells resulting in an increase of (i) recruitment of infiltrating immune cells, (ii) angiogenesis, (iii) tumor cell proliferation, 
(iv) EMT, and (v) tumor cell migration in the vascular bed and their journey to metastatic sites.
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(a blocking antibody) significantly reduced neoplastic cell 
invasion and angiogenesis in mice bearing a melanoma (138). 
Similarly, in a mice model of malignant mesothelioma, targeting 
CXCL8 by a neutralizing monoclonal antibody (mAb) decreased 
tumor progression (139). Subsequently, different agents, rang-
ing from chemotherapeutic drugs to pharmacologic or natural 
compounds with anti-inflammatory properties, were tested for 
their ability to inhibit CXCL8 production (Table 3).
Lowering CXCL8
The results obtained with CXCL8 neutralizing mAb were con-
sistently confirmed by studies aimed at lowering the secretion of 
CXCL8 by cancer cells. In human melanoma xenografts, a BRAF 
inhibitor, with anti-proliferative and anti-metastatic properties, 
inhibited CXCL8 synthesis (140). The administration of dehy-
droepiandrosterone, an adrenal hormone with a protective role 
against cancer, inhibited the secretion of several chemokines 
including CXCL8, which was paralleled by a reduction of breast 
cancer cells growth (141).
In vitro experiments also showed that Rhus coriaria (a fruit 
displaying anticancer effects) dose dependently inhibits CXCL8 
secretion in breast cancer cells; thus accounting, at least in part, 
for the inhibition of tumor growth and metastasis mediated by 
R. coriaria (142).
Metformin, an oral hypoglycemic agent traditionally used for 
the treatment of type 2 diabetes mellitus, was recently identified 
TAbLe 3 | CXL8-lowering agents tested in several types of cancer cells.
Compound Type of cancer cells Consequent anticancer effect Reference
BRAF inhibitors Melanoma cells Anti-proliferative and anti-metastatic (140)
Dehydroepiandrosterone Breast cancer cells Anti-proliferative (141)
Rhus coriaria Breast cancer cells Anti-proliferative and anti-metastatic (142)
Metformin Endometrial stromal cells, thyroid cells Not assessed (143)
1α,25-dihydroxyvitamin D3 Prostate cancer cells Anti-angiogenic (144)
Sunitinib Medullary thyroid cancer cells Anti-angiogenic, anti-proliferative (123)
Interferon-γ Thyroid cancer cells Anti-metastatic (121)
Oncolytic adenovirus dl922-947 Anaplastic thyroid cancer Anti-angiogenic, inhibition of macrophage infiltration (145)
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as an antitumor agent (146), which negatively modulates the 
secretion of CXCL8 in endometrial stromal cells (143). Similarly, 
vitamin 1α,25-OH-D3 was found to suppress CXCL8-mediated 
angiogenesis in prostate cancer cells (144). Sunitinib, a multi-
kinase inhibitor with both anti-angiogenic and antitumor activi-
ties, was demonstrated to strongly reduce CXCL8 secretion in 
medullary thyroid cancer cells (123). More importantly, CXCL8 
was identified as a potential biomarker of sunitinib responsive-
ness, because in vivo the circulating levels of CXCL8 dramatically 
decreased following sunitinib administration in medullary thy-
roid cancer xenografts (123). Taken together, these data strongly 
support the idea that CXCL8 might serve both as a potential 
therapeutic target and a clinical biomarker of some types of can-
cer. Therapeutic strategies aimed at lowering or targeting CXCL8 
represent a promising perspective for future antitumor therapies.
Strategies for Reducing CXCL8 Effects  
in Thyroid Cancer
Targeting CXCL8
The first proof that targeting CXCL8 within the tumor micro-
environment could produce therapeutic benefits was provided 
by Fang et al. in the previously mentioned study performed in 
NOD/SCID mice harboring thyroid cancer (51). Indeed, while 
the administration of rh-CXCL8 promoted tumor spread and 
reduced mice survival, targeting CXCL8 by a neutralizing Ab 
dose dependently reduced the metastatic spread of thyroid cancer 
cells and prolonged mice survival (51). More recently, Liotti et al. 
provided evidence that reparixin (an inhibitor of the CXCL8 
receptors, CXCR1, and CXCR2) reduces cell survival, prolifera-
tion, EMT, and stemness of several thyroid cancer cell lines (147). 
The specificity of this finding was demonstrated by the lack of any 
effect of reparaxin on viability of normal thyrocytes, which do 
not express CXCR1 and CXCR2 and by the fact that silencing of 
CXCR1 and CXCR2 abolished these effects.
Furthermore, reparixin significantly inhibited thyroid cancer 
cell tumorigenicity in immunodeficient mice. While potentiating 
of several chemotherapies on thyroid cancer cell xenotransplants 
in mice (147). Taken together, the above in  vitro and in  vivo 
findings would support the concept that targeting of CXCL8 
receptors could represent a potential therapeutic strategy at least 
for aggressive DTC.
Lowering CXCL8
Several attempts were done to reduce the secretion of CXCL8 in 
the thyroid tumor microenvironment. Among the tested agents, 
metformin recently received attention. In vitro ex vivo stud-
ies demonstrated that metformin directly inhibits the growth 
of cancer cells derived from papillary and follicular thyroid 
cancer specimens (148, 149), being this effect exerted via an 
AMPK-mediated inhibition of the mTOR signaling pathway 
(148). An additional indirect antitumor effect of metformin was 
demonstrated in a subsequent in vitro ex vivo study (150). Indeed, 
metformin significantly and dose dependently reduced the secre-
tion of CXCL8 induced by TNF-α in primary cultures of human 
thyroid cells obtained both from normal thyroid tissue and PTC 
surgical specimens. The same was not true in the thyroid tumor 
cell lines TPC-1 and BCPAP (150). At difference with metformin, 
AICAR (another AMPK activator with known anticancer proper-
ties) was recently demonstrated to inhibit CXCL8 secretion and 
cell migration in the thyroid tumor cell lines TPC-1 and BCPAP 
and in normal human thyroid cells (151). In line with the notion 
that CXCL8 promotes EMT (a crucial step in metastatization), 
the inhibition of cell migration by AICAR was observed only 
in those cells in which AICAR also inhibited CXCL8 secretion. 
These data would suggest that at least some of the anticancer 
effects of AICAR and inhibition of cell migration, in particular, 
would be exerted through the reduction of the CXCL8 levels.
Similarly, designed studies showed that IFN-γ does reduce 
the basal and the TNFα-stimulated secretion of CXCL8 both in 
normal thyroid cells and in BCPAP cells, but not in the TPC-1 
thyroid cancer cell line (121, 152). The specificity of IFN-γ as a 
CXCL8-lowering agent in BCPAP cells was further characterized 
by a migration assay performed both in basal conditions and after 
stimulation with the rh-CXCL8 protein. In these experiments, rh-
CXCL8 increased cell migration in both TPC-1 and BCPAP cells, 
but this effect was reverted by IFN-γ only in BCPAP cells (the 
ones in which IFN-γ also reduced CXCL8 secretion) (129). Taken 
together, the above results suggest that the pathways responsible 
for the secretion of CXCL8 differ in BCPAP cells, bearing the 
BRAF-V600E mutation, when compared with TPC-1 cells, 
bearing the RET/PTC rearrangement. This conclusion would 
fit with notions in human melanoma cells, which also bear the 
BRAF-V600E mutation and respond to a BRAF inhibitor with a 
reduced synthesis of CXCL8, thus resulting in anti-proliferative 
and anti-metastatic effects (140).
Additional evidences supporting the beneficial effects of 
lowering CXCL8 were provided also in anaplastic thyroid cancer 
cells. Indeed, it was recently reported that the oncolytic adenovi-
rus dl922-947 significantly lowered the synthesis of CXCL8 (and 
of CCL2 as well) by displacing the transcription factor NF-κB p65 
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from its specific promoters. The reduction of CXCL8 (and CCL2) 
was paralleled by impaired tumor angiogenesis and decreased 
macrophage density both in the in  vitro and in  vivo models 
of mice anaplastic thyroid cancer xenograft (145). Similarly, 
camptothecin, an inhibitor of DNA topoisomerase-I, besides 
decreasing anaplastic thyroid cell proliferation, apoptosis, adhe-
sion, and migration, it also lowers CXCL8 secretion in vitro. The 
inhibition of CXCL8 secretion by this compound would account 
for the decrease of tumor neoangiogenesis and vascularization 
in vivo (153).
At present, several agents, although with different strength of 
inhibition, turned out to be effective in reducing the secretion of 
CXCL8. However, none of them, at any concentration, was able 
to completely abolish the secretion of CXCL8. Failure to com-
pletely abolish CXCL8 secretion in the tumor microenvironment 
appears in line with the notion that CXCL8 secretion results from 
multiple intracellular signals and/or pathways, which appear to 
be different when normal or tumor cells are taken into account. 
In addition, among tumor cells, specific genetic lesions were found 
to be major determinants of the secretion of CXCL8 (86, 154). 
Initially, it was believed that the expression of CXCL8 mRNA in 
different thyroid cancer cell lines was mainly regulated by NF-κB. 
However, the fact that NF-κB interfering agents successfully 
inhibited CXCL8 secretion in some, but not all thyroid cell lines, 
suggested that multiple pathways are responsible for the secretion 
of CXCL8. These include, in adjunction to NF-κB signaling, the 
AP1, the hypoxia-inducible factor 1α, and the MAPK pathways 
(136, 150, 155).
CONCLUSive ReMARKS
The inflammatory tumor microenvironment consists of a 
mixture of immune cells and soluble mediators. In the latter 
group, chemokines represent key factors for tumor initiation, 
maintenance, and progression. Chemokines are a group of 
immune molecules secreted by both tumor and normal surround-
ing cells. At present, CCL2, CCL15, CCL20, CXCL1, CXCL8, 
CXCL12, and CXCL16 are the main chemokines showing a role 
in thyroid cancer. Among them, CXCL8, previously demon-
strated to exert several tumor-promoting effects in many human 
cancers, represents the most deeply investigated chemokine in 
thyroid tumor microenvironment. Differentiated thyroid cancers 
are the most prevalent endocrine malignancies being in most 
cases slow growing, clinically indolent lesions with an overall 
good prognosis and a very low-mortality rate. The availability of 
a marker of aggressiveness in the minority of patients harboring 
aggressive thyroid cancer would be welcome, because it would 
allow targeted therapies, while reducing the risk of over treating 
the vast majority of patients. Solid evidence from in  vitro and 
in vivo studies supports a major role for CXCL8 in determining 
a more aggressive clinical course of differentiated thyroid cancer. 
CXCL8 favors tumor progression through several mechanisms, 
which include the promotion of thyroid cancer metastatic spread 
and EMT (Figure 2). Targeting of CXCL8 in thyroid tumors pro-
vides therapeutic benefits in experimental models. Thus, several 
agents were tested for their efficacy in inhibiting the secretion 
of CXCL8 in the thyroid cancer microenvironment. Inhibiting 
CXCL8 secretion turned out to be more difficult than it could be 
envisaged, even if several compounds allowed a certain degree 
of inhibition of CXCL8 secretion by thyroid tumor cells. Given 
the crucial importance of tumor-related inflammatory microen-
vironment in determining tumor progression, it appears likely 
that research to address the issue of lowering CXCL8 secretion 
will continue in the future.
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